Table 1 Baseline patient characteristics.

From: Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study

 Whole cohort (n = 3,276)
Age (years)63 (54–71)
Female1,261 (38.5)
Dialysis duration (years)8.3 (3.7–14.3)
Serum albumin (mg/dL)3.8 (3.5–4.0)
Cardiovascular disease1,965 (60.0)
Hypertension2,613 (79.8)
Diabetes1,026 (31.3)
Cancer165 (5.0)
Single-pool Kt/V1.41 (1.23–1.58)
Body mass index (kg/m2)20.9 (19.0–23.3)
Corrected calcium (mg/dL)9.7 (9.1–10.4)
Corrected calcium 8.4–10 mg/dLa1,829 (55.8)
Phosphorus (mg/dL)5.5 (4.6–6.3)
Phosphorus 3.5–6 mg/dLa2,073 (63.3)
Intact PTH (pg/mL)265 (195–392)
Intact PTH 60–240 pg/mLa1,282 (39.1)
Cinacalcet use during the follow-up1,384 (42.3)
Intravenous Vitamin D use at baseline1,596 (48.7)
Phosphate binder use at baseline2,995 (85.3)
  1. Values are presented as median (range) or n (%).
  2. aThe targets of bone mineral markers used here were those outlined in the Japanese clinical guidelines.
  3. PTH, parathyroid hormone.